Increased luminescence of the GloSensor cAMP assay in LβT2 cells does not correlate with cAMP accumulation under low pH conditions

Shiori MUSHA1), Syo MURAKAMI1), Ryotaro KOJIMA1) and Hideaki TOMURA1, 2)

1)Laboratory of Cell Signaling Regulation, Department of Life Sciences, School of Agriculture, Meiji University, Kawasaki 214-8571, Japan
2)Institute of Endocrinology, Meiji University, Kawasaki 214-8571, Japan

Abstract. Cyclic adenosine monophosphate (cAMP) plays a pivotal role in gonadotrope responses in the pituitary. Gonadotropin-releasing hormone (GnRH) mediated synthesis and secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) are regulated by both the Gs/cAMP and Gq/Ca2+ signaling pathways. Pituitary adenylate cyclase-activating polypeptide (PACAP) also regulates GnRH responsiveness in gonadotropes through the PACAP receptor, which activates the Gs/cAMP signaling pathway. Therefore, measuring intracellular cAMP levels is important for elucidating the molecular mechanisms of FSH and LH synthesis and secretion in gonadotropes. The GloSensor cAMP assay is useful for detecting cAMP levels in intact, living cells. In this study, we found that increased GloSensor luminescence intensity did not correlate with cAMP accumulation in LβT2 cells under low pH conditions. This result indicates that cell type and condition must be considered when using GloSensor cAMP.

Key words: Cyclic adenosine monophosphate (cAMP), GloSensor, Low pH, Luminescence, LβT2

Cyclic adenosine monophosphate (cAMP) is a second messenger that plays important roles in numerous biological processes [1]. In the pituitary, adrenocorticotropic hormone (ACTH) is synthesized and secreted from corticotropes following stimulation by corticotropin-releasing hormone (CRH) acting through the Gs/cAMP signaling pathway [2]. In gonadotropes, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) synthesis and gonadotropin-releasing hormone (GnRH)-mediated secretion are regulated by both the Gs/cAMP and Gq/Ca2+ signaling pathways. The cAMP and Ca2+ signaling pathways are influenced by the pulse frequencies of GnRH stimulation [3]. Pituitary adenylyl cyclase-activating polypeptide (PACAP) is a hypothalamic pituitary-releasing factor, as well as an autocrine/paracrine factor within the pituitary, and regulates GnRH responsiveness through the PACAP receptor by increasing GnRH receptor expression and modulating GnRH intracellular signaling pathways [4]. The PACAP receptor is also mainly coupled to, and activates, the Gs/cAMP signaling pathway [5]. This indicates that cAMP plays a pivotal role in corticotrope and gonadotrope responses in the pituitary; consequently, measuring intracellular cAMP levels in real time becomes especially important for elucidating the molecular mechanisms of FSH and LH synthesis and secretion in gonadotropes.

The cellular levels of cAMP are typically quantified by radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA). These methods show high specificity and sensitivity for the quantification of cAMP concentrations. However, a cAMP-specific antibody is needed with both methods, and additionally, cells must be lysed before quantification, with the result that changes in intracellular cAMP levels cannot be followed in real time using RIA and/or ELISA. The GloSensor cAMP assay uses genetically encoded biosensor variants with cAMP-binding domains fused to mutant Photinus pyralis luciferase. On binding to cAMP, this enzyme undergoes conformational changes, leading to increased bioluminescence [6]. Thus, cells expressing the GloSensor plasmid can be used to evaluate cAMP levels in living cells in real time and without having to lyse the cells. Indeed, the GloSensor reporter has been utilized in numerous studies, including for the characterization of adenosine receptor antagonists expressed in native cells [7], the cAMP inducer-free screening of Gq-coupled receptor agonists [8], and the testing of selective agonists for the κ-opioid receptor [9]. Although the cAMP GloSensor has not been used in corticotropes and gonadotropes, its application is expected to provide useful information for elucidating the role of changes in cAMP levels in these hormone-producing cells in real time.

The OGR1, GPR4, and TDAG8 proteins are recognized as proton-sensing G protein-coupled receptors (GPCRs) that sense extracellular protons and activate intracellular signaling pathways through trimeric G proteins [10, 11]. These GPCRs are inactive at alkaline pH (pH 7.8), partially activated at physiological pH (pH 7.4), and fully activated at approximately pH 6.8 [10, 11]. The OGR1 receptor is mainly coupled to, and activates, the Gq/cAMP signaling pathway when stimulated by extracellular protons. In contrast, GPR4 and TDAG8 are mainly coupled to, and activate, the Gs/cAMP signaling pathway when stimulated by extracellular protons [10, 11]. Expression of TDAG8 is detected mainly in immune cells [12].
while that of GPR4 is widely detected in various tissues [13]. Under conditions of low pH, GPR4 has been shown to ameliorate intestinal inflammation [13], mediate central respiratory sensitivity to CO2 [14, 15], and inhibit osteogenesis [16]. Moreover, GPR4 antagonists are reported to protect against myocardial infarction [17, 18] and exhibit modulatory effects in models of arthritis, hyperalgesia, and angiogenesis [19]. In relation to hormonal function, GPR4 increases insulin sensitivity [20].

In this study, we used the mouse LβT2 gonadotrope and the AtT20 corticotrope cell lines. LβT2 cells secrete LH following GnRH stimulation [21] and are also responsive to PACAP [22]. AtT20 cells, meanwhile, secrete ACTH when stimulated with CRH [23]. We found that the bioluminescence of the GloSensor reporter increased with decreasing extracellular pH in LβT2 cells, but not in AtT20 cells.

We first examined which proton-sensing GPCRs are expressed in LβT2 cells. As shown in Fig. 1A, expression of OGR1 and Gpr4 was observed in LβT2 cells, whereas that of TDAG8 was barely detected. We next examined the expression level of Gpr4 in LβT2 and AtT20 cells as GPR4 is mainly coupled to the Gs/adenylyl cyclase/cAMP signaling pathway. No difference in Gpr4 expression was observed between the two cell lines, with levels approximately one-fifth of those observed in the mouse anterior pituitary lobe (Fig. 1B).

In LβT2 cells, when the extracellular pH decreased, GloSensor luminescence, which is assumed to reflect cAMP accumulation, increased in a time-dependent manner (Fig. 2A). The peak level of luminescence induced by low pH was more than that induced by PACAP; however, it takes longer to reach the peak induced by low pH than the peak induced by PACAP (Fig. 2A). This result suggests that low pH induces greater cAMP accumulation than PACAP in LβT2 cells. The intensity of the luminescence induced by PACAP was further increased under conditions of low pH (Fig. 2B), suggesting that low pH enhances PACAP-induced cAMP accumulation in LβT2 cells. In contrast, the luminescence intensity in AtT20 cells was only marginally increased under low extracellular pH (Fig. 2C). This was not due to a lack of a response to cAMP accumulation in AtT20 cells; indeed, luminescence was shown to increase following CRH stimulation, which is known to induce cAMP accumulation in AtT20 cells [24]. This result indicates that the increased luminescence observed under low pH is not consistent with the expression levels of Gpr4 in both LβT2 and AtT20 cells.

We next used a GPR4 antagonist [17] to clarify whether the low pH-induced increase in luminescence in LβT2 cells was mediated by GPR4. The results showed that low pH- and PACAP-induced luminescence were only marginally affected by exposure to 10 µM of the antagonist, a concentration that is normally sufficient to inhibit GPR4 activity [18] (Fig. 3A and 3B). Indeed, when we compared the peak level of luminescence induced by low pH in the presence or absence of the antagonist, the luminescence intensities were not attenuated by the antagonist (Fig. 3C).

Next, to examine whether the low pH-induced increase in luminescence in LβT2 cells reflected cAMP accumulation, we measured cAMP levels in both LβT2 and AtT20 cells using ELISA. As shown in Fig. 4A and 4C, a 30 min incubation at low pH did not elicit cAMP accumulation in either cell line. Conversely, cAMP accumulation was induced by both PACAP (Fig. 4A) and CRH (Fig. 4C), while low pH inhibited cAMP accumulation by both PACAP and CRH (Fig. 4A and 4C). As shown in Fig. 4B and 4D, similar results were obtained when we cAMP levels were measured 15 min after incubation, where GloSensor luminescence showed near peak values (Fig. 2). Thus, the ELISA result is different from the that of GloSensor in LβT2 cells.

To compare the GloSensor and ELISA results, we further examined the effect of forskolin which is a diterpenoid isolated from Coleus forskohlii. Forskolin is used for activating adenylyl cyclase directly to produce cAMP in a cell. As shown in Fig. 5A–5C, forskolin application resulted in increased GloSensor luminescence in LβT2, AtT20, and HEK293T cells, with luminescence peaking approximately 10 min after addition of the reagent. Accumulation of cAMP in these cells after 10 min of incubation with or without forskolin was also evaluated by ELISA. The result indicated that cAMP accumulation increased in the presence, but not absence, of the reagent (Fig. 5D–5F). The result also indicated that the level of cAMP accumulation after 10 min without the reagent was almost equal to that at the beginning (0 min) of incubation in these cell lines (Fig. 5D–5F).

We also examined the possibility that the increase in luminescence in LβT2 cells resulting from a low pH may have reflected cGMP accumulation rather than that of cAMP. GloSensor variants can sense cGMP in addition to cAMP, although the sensitivity to cGMP is less than 100-fold that of cAMP [6]. The result is shown in Fig. 6. Neither low pH nor PACAP induced cGMP accumulation under the condition in which atrial natriuretic peptide (ANP) induced its accumulation in LβT2 cells [25].

The results indicate that the increase in GloSensor luminescence at low pH did not correlate with the quantity of cAMP or cGMP produced in LβT2 cells. To elucidate the mechanism by which low pH induces...
increased luminescence in LβT2 cells, we examined the possibility that the uptake of the GloSensor cAMP substrate into the cells may be enhanced by decreasing pH. When we removed the substrate from the assay medium before measuring the luminescence, the total luminescence in the cells decreased (Fig. 7A and 7B); however, the increased luminescence induced by low pH was still observed (Fig. 7B), similar to that seen in the presence of the substrate (Fig. 7A). This result indicates that changing substrate uptake is not the cause of the increased luminescence at low pH seen in LβT2 cells.

The GloSensor cAMP assay has been utilized in numerous studies [7–9] and is useful for monitoring cAMP levels in cells in real time. In the present study, we showed that GloSensor cAMP luminescence was increased in LβT2, but not AtT20 cells, under conditions of low pH. The degree of the increase in luminescence at low pH was greater than that induced by PACAP (Fig. 2A). In addition, low pH further increased the PACAP-induced luminescence (Fig. 2B), whereas when we measured the levels of cAMP or cGMP in LβT2 cells under conditions of low pH, we could not detect any increased accumulation of either cAMP or cGMP. One possible explanation for the increased luminescence at low pH was that the permeability of LβT2 cells to the GloSensor cAMP substrate was enhanced. This possibility is low, however, as indicated in Fig. 7. Even though we removed the substrate from the assay medium before measuring the luminescence, low pH still induced increased luminescence in LβT2 cells (Fig. 7B). Therefore, the mechanism by which low pH increases luminescence in LβT2 cells remains unknown. It is possible that the GloSensor may detect undefined factors other than cAMP or cGMP in LβT2 cells, but not in AtT20 and HEK293T cells. Another possibility may be that the biosensor might detect a local increase in cAMP levels in LβT2 cells that cannot be detected at the whole-cell level. Although cAMP can easily diffuse in the cytosol, cAMP also confines in microdomains near the sites of its production in a cell. This confined cAMP plays a role in activating several effectors [26]. The increased GloSensor luminescence in LβT2 cells may also reflect localized cAMP accumulation in microdomains in the cell. This possibility could be clarified using different optical methods, such as the fluorescence resonance energy transfer (FRET), which can detect local cellular cAMP accumulation [26].

GPR4 is recognized as a proton-sensing GPCR that predominantly couples with Gs to induce cAMP accumulation. In this study, we
could not detect any cAMP accumulation under low pH conditions using ELISA, despite Gpr4 being expressed in both LβT2 and AtT20 cells (Fig. 1); however, this result does not necessarily indicate that GPR4 is not active in LβT2 or AtT20 cells. Gpr4 expressed in human umbilical vein endothelial cells (HUVECs) is known to be involved in cell adhesion through the cAMP/Epac pathway [14, 27]. Although the HUVEC is known as a cell that strongly expresses endogenous Gpr4 [27], cAMP accumulation due to low pH is only approximately 1.5-fold to its base level, lower than that in HEK293 cells overexpressing Gpr4. Low pH induces an accumulation of cAMP of approximately four fold in HEK293 cells [14]. Therefore, a small increase in cAMP levels is enough to induce the response observed for the HUVECs. It is possible that Gpr4 expressed in LβT2 or AtT20 cells may induce local cAMP accumulation that cannot be detected by ELISA, as mentioned above. Local cAMP accumulation would play a role in activating some effectors in these cells. To elucidate the role of Gpr4 expression in LβT2 or AtT20 cells, other methods must be used, such as the FRET method mentioned above.

In conclusion, we have shown that, in LβT2 cells, the low pH-induced increase in luminescence using GloSensor cAMP does not correlate with cellular cAMP accumulation when measured by ELISA. The results in this study indicate that the cell type and condition must be considered when cAMP production is measured using GloSensor cAMP.

Materials and Methods

Materials

Human pituitary adenylate cyclase-activating polypeptide (PACAP38) and human atrial natriuretic peptide (human ANP) were purchased from Sigma-Aldrich (Tokyo, Japan), human corticotropin-releasing hormone (human CRH) from the PEPTIDE INSTITUTE (Osaka, Japan), forskolin (FSK) from FUJIFILM Wako (Osaka, Japan), the pGloSensor-22F-cAMP plasmid and GloSensor cAMP.
cAMP-INDEPENDENT LUMINESCENCE INCREASE

reagent from Promega (Tokyo, Japan), a dual luciferase kit from Promega (Tokyo, Japan), fatty acid-free Bovine serum albumin (BSA) from Calbiochem-Novabiochem Co. (San Diego, CA, USA), and Lipofectamine 2000 transfection reagent from Life Technologies (Tokyo, Japan). The sources of all the other reagents were as previously described [28, 29].

Quantitative real-time polymerase chain reaction

Quantitative real-time PCR was performed as described by Yoshida et al. [30]. Briefly, total RNA was prepared from LβT2 and AtT20 cells using ISOGEN II (Nippon Gene, Tokyo, Japan). cDNA was synthesized with PrimeScript Reverse Transcriptase (TaKaRa Bio, Otsu, Japan) using 1 µg of total RNA after DNase I treatment, and then subjected to quantitative PCR using a StepOnePlus Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). Reactions were performed in a SYBR Green Real-Time PCR Master Mix Plus (Toyobo, Osaka, Japan), including 0.5 µM of gene-specific primer sets. The sequences of the primers used in this study are as follows (5’–3’): OGR1 forward ACCGAGTCTGCTTTGAGCAT, reverse AAGACCAAGCCAGAGATGA; TDAG8 forward TGGGCTACGCAATACCCTTG, reverse CTAAAACGCAGCGGATGAGC; GPR4 forward GCAAGCTCTTTGGCTTCATC, reverse GTGTTGTTTGTGACTCATGA; and TBP forward GATCAGAGTCTTCTATCC, reverse ATGTGGTCTTCCTGAATCCC. The expected sizes of the OGR1, TDAG8, and GPR4 amplicons were 218, 189, and 229 bp, respectively. Quantification of the PCR products was performed using the comparative CT method (ΔCT method) to estimate the mRNA copy number relative to that of the TATA box binding protein gene (Tbp) used as an internal standard (Fig. 1B). Each PCR product was validated by sequencing (data not shown).

Cell culture

LβT2, AtT20, and HEK293T cells were maintained in culture medium consisting of Dulbecco’s modified Eagle’s medium (DMEM) containing 50 ng penicillin/ml, 50 ng streptomycin/ml, and 10% fetal bovine serum (FBS). All the cells were grown in 5% CO2 at 37°C in a humidified environment.

GloSensor cAMP assay

The pGloSensor-22F-cAMP plasmid (1 µg) was transfected into LβT2, HEK293T, or AtT20 cells (1.5 × 10⁶ cells) using the Lipofectamine 2000 reagent as previously described [28]. Two days after transfection, cells expressing the GloSensor were seeded in culture medium (100 µl/well) in a poly-D-lysine pre-coated 96-well, clear-bottomed white wall microplate and incubated overnight in 5% CO2 at 37°C in a humidified environment. On the day of the cAMP assay, the culture medium was changed to a culture medium...
containing 2% GloSensor cAMP substrate and pre-incubated for 2 h at 37°C. The pre-incubated medium was then changed to the culture medium (25°C) at the indicated pH, containing 500 µM 3-isobutyl-1-methylxanthine (IBMX) and 2% GloSensor cAMP substrate in the presence or absence of PACAP (100 nM), CRH (100 nM), forskolin (10 µM), or the GPR4 antagonist (10 µM) at 25°C. To evaluate the effect of the GloSensor cAMP substrate on the increase in luminescence at low pH, the GloSensor cAMP substrate was removed to eliminate the changes in substrate uptake occurring at low pH (Fig. 7). To adjust the pH of the culture medium, an ap-

![Figure 5](image1.png)  
**Fig. 5.** Effect of forskolin (FSK) on cAMP accumulation in LβT2 (A, D), AtT20 (B, E), and HEK293T (C, F) cells. FSK-induced cAMP accumulation was measured using GloSensor cAMP (A–C). The cells were stimulated with 10 µM FSK. Data are the means ± SE of triplicate measurements obtained in a single representative experiment. The quantity of cAMP at the beginning (0 min) or after 10 min of incubation either with or without 10 µM FSK was measured by ELISA (D–F). Data are the means ± SE of 3 separate experiments.

![Figure 6](image2.png)  
**Fig. 6.** Effect of low pH on cGMP accumulation in LβT2 cells. The cells were stimulated with the indicated pH in the presence or absence of 100 nM PACAP (A) or 1 µM ANP for 30 min. Data are the means of duplicate measurements obtained in a single representative experiment (A) or the means ± SE of triplicate measurements (B). Asterisks (*) indicate that the level of cGMP was significantly different (B). * P < 0.05
cAMP-INDEPENDENT LUMINESCENCE INCREASE

Fig. 7. Effect of the GloSensor cAMP substrate on the increase in luminescence at low pH. The low pH-induced increase in luminescence was measured in the presence (A) or absence (B) of the GloSensor cAMP substrate. LβT2 cells were pre-loaded with the substrate during the pre-incubation period. The substrate was then removed in (B), but not in (A), before the luminescence was measured. Data represent the means ± SE of triplicate measurements obtained in a single representative experiment and expressed as relative luminescence units (RLU). Similar data were obtained in two separate experiments (A, B).

The appropriate amount of 1 M HCl was added to the medium immediately prior to luminescence measurement. Luminescence was measured continuously over 30 min at 25°C, averaging 1 read per well every 2 min, using an Envision Multilabel plate reader (Perkin Elmer, Waltham, MA, USA).

ELISA

LβT2 cells were pre-incubated in Hepes-Regular at pH 7.4 (500 µM/well) for 15 min in 12-well multiplates. The Hepes-Regular was composed of 25 mM HEPES, 134 mM NaCl, 4.7 mM KCl, 1.2 mM KH₂PO₄, 1.2 mM MgSO₄, 2 mM CaCl₂, 2.5 mM NaHCO₃, 5 mM glucose, and 0.1% (w/v) BSA. Then, the Hepes-Regular was replaced with 200 µl of Hepes-Regular at the indicated pH and containing 500 µM IBMX, in the presence or absence of 100 nM PACAP or 1 µM ANP, and incubated for a further 15 or 30 min. After stimulation, the cells were lysed in 1 ml of 1 M HCl, and the lysed samples were used for cAMP or cGMP determination. The quantity of cAMP or cGMP in the cells was estimated using direct cAMP or cGMP ELISA kits (Enzo Life Science, Farmingdale, NY, USA).

Data presentation

The results of multiple observations are presented either as the means ± SE or as a representative result, as indicated in the figure legends. Statistical significance was assessed by the Student’s t-test (Fig. 6B). The values were considered significant at P < 0.05 (*).

Acknowledgments

LβT2 cells were a generous gift from Dr Pamela Mellon, UCSD. HEK293T cells were provided by the RIKEN BRC through the National Bio-Resource Project of MEXT, Japan. The GPR4 antagonist was kindly provided by Dr Satoshi Shuto, Hokkaido University. Mouse anterior pituitary lobe cDNA (130 days after birth) was kindly provided by Dr Saishu Yoshida, Jikei University. This work was supported in part by Grants-in-Aid (C) for Scientific Research from the Japan Society for the Promotion of Science Grant Number 15K07772 and the MEXT-Supported Program for the Strategic Research Foundation at Private Universities, 2014–2018 (S1411021).

References

1. Zhang F, Zhang L, Qi Y, Xu H. Mitochondrial cAMP signaling. Cell Mol Life Sci 2016; 73: 4577–4590. [Medline] [CrossRef]
2. King MS, Baertelschi AJ. The role of intracellular messengers in adrenocorticotropin secretion in vitro. Experientia 1990; 46: 26–40. [Medline] [CrossRef]
3. Tsutsumi R, Mistry D, Webster NJ. Signaling responses to pulsatile gonadotropin-releasing hormone in LbetaT2 gonadotrope cells. J Biol Chem 2010; 285: 20262–20272. [Medline] [CrossRef]
4. Halvorsen LM. PACAP modulates GnRH signaling in gonadotropes. Mol Cell Endocrinol 2014; 385: 45–55. [Medline] [CrossRef]
5. Ramos-Alvarez I, Mantey SA, Nakamura T, Nuchee-Berenguer B, Moreno P, Moody TW, Maderdrut JL, Coy DH, Jensen RT. A structure-function study of PACAP using conformationally restricted analogs: Identification of PAC1 receptor-selective PACAP agonists. Peptides 2015; 66: 26–42. [Medline] [CrossRef]
6. Fan F, Blinkowski BF, Butler BL, Stepha PF, Lewis MK, Wood KV. Novel genetically encoded biosensors using firefly luciferase. ACS Chem Biol 2008; 3: 346–351. [Medline] [CrossRef]
7. Goulding J, May LT, Hill SJ. Characterisation of endogenous A1a and A9a receptor-mediated cyclic AMP responses in HEK 293 cells using the GloSensor™ biosensor: Evidence for an allosteric mechanism of action for the A9a-selective antagonist PSB 603. Biochem Pharmacol 2018; 147: 55–66. [Medline] [CrossRef]
8. Gilsassen J, Geuhelle P, Dupuis N, Laschet C, Pirotte B, Hansson J. Forskolin-free cAMP assay for Gα-coupled receptors. Biochem Pharmacol 2015; 98: 381–391. [Medline] [CrossRef]
9. White KL, Scopion AP, Rives ML, Bikbulatov RV, Polepally FR, Brown PJ, Kenakin T, Javitch JA, Zajwiony JK, Roth BL. Identification of novel functionally selective α-opioid receptor scaffolds. Mol Pharmacol 2014; 85: 83–90. [Medline] [CrossRef]
10. Ludwig MG, Vaneck M, Guerini D, Gasser JA, Jones CE, Junker U, Hofstetter H, Wolf RM, Seuwem K. Proton-sensing G-protein-coupled receptors. Nature 2003; 425: 93–98. [Medline] [CrossRef]
11. Wang JQ, Kon J, Mogi C, Tobo M, Damirin A, Sato K, Komachi M, Malchinkhuu E, Murata N, Kinuma T, Kavabara A, Wakamatsu K, Koizumi H, Uede T, Tsujimoto G, Kurose H, Sato T, Harada A, Misawa N, Tomura H, Okajima F. TDAG8 is a proton-sensing and psychosine-sensitive G-protein-coupled receptor. J Biol Chem 2004; 279: 45626–45633. [Medline] [CrossRef]
12. Tomura H, Mogi C, Sato K, Okajima F. Proton-sensing and lysolipid-sensitive G-protein-coupled receptors: a novel type of multi-functional receptors. Cell Signal 2005; 17: 1466–1476. [Medline] [CrossRef]
13. Wang Y, de Vallière C, Imenez Silva PH, Leonard I, Gruber S, Gerstgrasser A, Melhem H, Weber A, Leucht K, Wolfram L, Hausmann M, Krieg C, Thomasson K, Boyman O, Frey-Wagner I, Rogler G, Wagner CA. The Proton-activated Receptor GPR4 Modulates Intestinal Inflammation. J Clinin. Catabis 2018; 12: 355–368. [Medline]
14. Hofsord PS, Mosienko V, Kishi K, Jurisie G, Seuwen K, Kinzel B, Ludwig MG, Wells JA, Christie FN, Koolen L, Abdala AP, Liu BH, Gourine AV, Teschemacher AG, Kasparov S. CNS distribution, signalling properties and central effects of G-protein coupled receptor 4. Neuropharmacology 2018; 138: 381–392. [Medline] [CrossRef]

15. Sanderlin EJ, Leffler NR, Lertrpiyapong K, Cai Q, Hong H, Baktihavatchalu V, Fox JG, Oswald JZ, Justus CR, Krewson EA, O’Rourke D, Yang LV. GPR4 deficiency alleviates intestinal inflammation in a mouse model of acute experimental colitis. Biochim Biophys Acta Mol Basis Dis 2017; 1863: 569–584. [Medline] [CrossRef]

16. Tao SC, Gao YS, Zhu HY, Yin JH, Chen XY, Zhang YL, Guo SC, Zhang CQ. Decreased extracellular pH inhibits osteogenesis through proton-sensing GPR4-mediated suppression of yes-associated protein. Sci Rep 2016; 6: 26835. [Medline] [CrossRef]

17. Fukuda H, Ito S, Watari K, Mogi C, Ariuwa M, Okajima F, Kuruse H, Shuto S. Identification of a Potent and Selective GPR4 Antagonist as a Drug Lead for the Treatment of Myocardial Infarction. ACS Med Chem Lett 2016; 7: 493–497. [Medline] [CrossRef]

18. Tobo A, Tobo M, Nakamura T, Ebara M, Tomura H, Mogi C, Im DS, Murata N, Kuwabara A, Ito S, Fukuda H, Ariuwa M, Shuto S, Nakaya M, Kuruse H, Sato K, Okajima F. Characterization of imidazopyridine compounds as negative allosteric modulators of proton-sensing GPR4 in extracellular acidification-induced responses. PLoS One 2015; 10: e0129334. [Medline] [CrossRef]

19. Velický J, Mittl W, Oberhauser B, Grain D, Vaupel A, Weigand K, Dawson King J, Littlewood-Exans A, Nash M, Feilr F, Loetscher P. Development of selective, orally active GPR4 antagonists with modulatory effects on nociception, inflammation, and angiogenesis. J Med Chem 2017; 60: 3672–3683. [Medline] [CrossRef]

20. Giudici L, Velic A, Daryadel A, Bettoun C, Mohbebi N, Suply T, Seuwen K, Ludwig MG, Wagner CA. The proton-activated receptor GPR4 modulates glucose homeostasis by increasing insulin sensitivity. Cell Physiol Biochem 2013; 32: 1403–1416. [Medline] [CrossRef]

21. Alarid ET, Windle JJ, Whyte DB, Mellon PL. Immortalization of pituitary cells at discrete stages of development by directed oncogenesis in transgenic mice. Development 1996; 122: 3319–3329. [Medline]

22. Kanasaki H, Mutiara S, Oride A, Purwana IN, Miyazaki K. Pulse frequency-dependent gonadotropin gene expression by adenylate cyclase-activating polypeptide 1 in perfused mouse pituitary gonadotroph LbetaT2 cells. Biol Reprod 2009; 81: 465–472. [Medline] [CrossRef]

23. Ray DW, Ren SG, Melmed S. Leukemia inhibitory factor (LIF) stimulates proopiomelanocortin (POMC) expression in a corticotroph cell line. Role of STAT pathway. J Clin Invest 1996; 97: 1852–1859. [Medline] [CrossRef]

24. Aoki Y, Iwasaki Y, Katabira M, Oiso Y, Saito H. Regulation of the rat proopiomelanocortin gene expression in AtT-20 cells. 1: Effects of the common secretagogues. Endocrinology 1997; 138: 1923–1929. [Medline] [CrossRef]

25. Thompson IR, Chand AN, Jonas KC, Burrin JM, Steinhelper ME, Wheeler-Jones CP, Mcardle CA, Fowkes RC. Molecular characterisation and functional interrogation of a local natriuretic peptide system in rodent pituitaries, αT3-1 and LβT2 gonadotroph cells. J Endocrinol 2009; 203: 215–229. [Medline] [CrossRef]

26. Calebiro D, Maiellaro I. cAMP signaling microdomains and their observation by optical methods. Front Cell Neurosci 2014; 8: 350. [Medline] [CrossRef]

27. Chen A, Dong L, Leffler NR, Asch AS, Witte ON, Yang LV. Activation of GPR4 by acidosis increases endothelial cell adhesion through the cAMP/Epac pathway. PLoS One 2011; 6: e27586. [Medline] [CrossRef]

28. Tobo M, Tomura H, Mogi C, Wang JQ, Liu JP, Komachi M, Damirin A, Kimura T, Murata N, Kuruse H, Sato K, Okajima F. Previously postulated “ligand-independent” signaling of GPR4 is mediated through proton-sensing mechanisms. Cell Signal 2007; 19: 1745–1753. [Medline] [CrossRef]

29. Liu JP, Nakakura T, Tomura H, Tobo M, Mogi C, Wang JQ, He XD, Takano M, Damirin A, Komachi M, Sato K, Okajima F. Each one of certain histidine residues in Gprotein-coupled receptor GPR4 is critical for extracellular proton-induced stimulation of multiple G-protein-signaling pathways. Pharmacol Res 2010; 61: 499–505. [Medline] [CrossRef]

30. Yoshida S, Fujiwara K, Nishihara H, Kato T, Yashiro T, Kato Y. Retinoic acid signaling is a candidate regulator of the expression of pituitary-specific transcription factor Propl in the developing rodent pituitary. J Neuroendocrinol 2018; 30: e12570. [Medline] [CrossRef]